Neurocast has launched its new technology at the Consumers Electronics Show (CES) – in 2023.
This will aid in passively monitoring diseases like multiple sclerosis, Alzheimer’s, and even depression.
“We believe that much of the data that could tell us something about how you are doing – mentally, physically, or emotionally – is hidden in how we interact with technology,” reads Neurocast’s website.
“Our mission [is] to turn everyday digital interactions into clinically approved outcomes, enabling doctors & researchers to passively measure individual patients’ performance in daily life. With our technology, this can be done completely unobtrusive, with privacy embedded by design and available for everyone to join.”
The first can be used to measure primary and secondary clinical endpoints within clinical trials. The second provides data in real-world scenarios allowing doctors to monitor their patients and proactively act on status changes.
To achieve all this, Neurocast started with the smartphone as it is the most commonly used device.
“We started with the most frequently used device, being the smartphone, meanwhile adding other devices that have become an unseen part of our daily lives, such as computers and smartwatches,” said the web portal.
Neurocast says it does not collect data that can be traced back to individual patients and is GDPR and HIPAA-compliant. It is also ISO 27001 certified.
“73 percent of patients have valid concerns about privacy and security. It is often unclear what kind of data is used, for what purpose, and with whom it is shared. Safety is of paramount importance at Neurocast,” further adds the firm’s website.
Neurocast has also collaborated with leading institutes such as Amsterdam UMC. They are working on implementation validation with their customers, to ensure fast integration of the technology.